Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin plus irinotecan versus irinotecan alone in previously treated extensive-stage small-cell lung cancer
ChiCTR2300074309Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atorvastatin and irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Safety and Overall survival. Started Jul 2023; status: recruiting.
02
Drugs
atorvastatinirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300074309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074309.